Search

Your search keyword '"Sjöwall, Christopher"' showing total 595 results
Start Over Author "Sjöwall, Christopher"
595 results on '"Sjöwall, Christopher"'

3. Low CD4 + T cell count is related to specific anti-nuclear antibodies, IFNα protein positivity and disease activity in systemic lupus erythematosus pregnancy

Author

Torell, Agnes, Stockfelt, Marit, Blennow, Kaj, Zetterberg, Henrik, Akhter, Tansim, Leonard, Dag, Rönnblom, Lars, Pihl, Sofia, Saleh, Muna, Sjöwall, Christopher, Strevens, Helena, Jönsen, Andreas, Bengtsson, Anders A., Trysberg, Estelle, Majczuk Sennström, Maria, Zickert, Agneta, Svenungsson, Elisabet, Gunnarsson, Iva, Bylund, Johan, Jacobsson, Bo, Rudin, Anna, and Lundell, Anna-Carin

Published
2024
Full Text
View/download PDF

4. Low-density granulocytes are related to shorter pregnancy duration but not to interferon alpha protein blood levels in systemic lupus erythematosus

Author

Torell, Agnes, Stockfelt, Marit, Larsson, Gunilla, Blennow, Kaj, Zetterberg, Henrik, Leonard, Dag, Rönnblom, Lars, Saleh, Muna, Sjöwall, Christopher, Strevens, Helena, Jönsen, Andreas, Bengtsson, Anders A., Trysberg, Estelle, Sennström, Maria Majcuk, Zickert, Agneta, Svenungsson, Elisabet, Gunnarsson, Iva, Christenson, Karin, Bylund, Johan, Jacobsson, Bo, Rudin, Anna, and Lundell, Anna-Carin

Published
2023
Full Text
View/download PDF

6. A survey of ficolin-3 activity in Systemic Lupus Erythematosus reveals a link to hematological disease manifestations and autoantibody profile

Author

Lindelöf, Linnea, Rantapää-Dahlqvist, Solbritt, Lundtoft, Christian, Sandling, Johanna K., Leonard, Dag, Sayadi, Ahmed, Rönnblom, Lars, Enocsson, Helena, Sjöwall, Christopher, Jönsen, Andreas, Bengtsson, Anders A., Hong, Mun-Gwan, Diaz-Gallo, Lina-Marcela, Bianchi, Matteo, Kozyrev, Sergey V., Lindblad-Toh, Kerstin, Nilsson Ekdahl, Kristina, Nilsson, Bo, Gunnarsson, Iva, Svenungsson, Elisabet, and Eriksson, Oskar

Published
2024
Full Text
View/download PDF

11. Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort

Author

Wirestam, Lina, Enocsson, Helena, Skogh, Thomas, Padyukov, Leonid, Jönsen, Andreas, Urowitz, Murray B, Gladman, Dafna D, Romero-Diaz, Juanita, Bae, Sang-Cheol, Fortin, Paul R, Sanchez-Guerrero, Jorge, Clarke, Ann E, Bernatsky, Sasha, Gordon, Caroline, Hanly, John G, Wallace, Daniel, Isenberg, David A, Rahman, Anisur, Merrill, Joan, Ginzler, Ellen, Alarcón, Graciela S, Chatham, W Winn, Petri, Michelle, Khamashta, Munther, Aranow, Cynthia, Mackay, Meggan, Dooley, Mary Anne, Manzi, Susan, Ramsey-Goldman, Rosalind, Nived, Ola, Steinsson, Kristjan, Zoma, Asad, Ruiz-Irastorza, Guillermo, Lim, Sam, Kalunian, Ken, Inanc, Murat, van Vollenhoven, Ronald, Ramos-Casals, Manuel, Kamen, Diane L, Jacobsen, Søren, Peschken, Christine, Askanase, Anca, Stoll, Thomas, Bruce, Ian N, Wetterö, Jonas, and Sjöwall, Christopher

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Autoimmune Disease, Kidney Disease, Lupus, Clinical Research, Inflammatory and immune system, Adolescent, Adult, Age Factors, Aged, Asia, Biomarkers, Child, Cross-Sectional Studies, Disease Progression, Enzyme-Linked Immunosorbent Assay, Europe, Female, Follow-Up Studies, Humans, Internationality, Logistic Models, Lupus Erythematosus, Systemic, Male, Middle Aged, Multivariate Analysis, North America, Osteopontin, Reference Values, Severity of Illness Index, Sex Factors, Young Adult, SYSTEMIC LUPUS ERYTHEMATOSUS, BIOMARKERS, OSTEOPONTIN, DISEASE ACTIVITY, ORGAN DAMAGE, PROGNOSIS, Immunology, Public Health and Health Services, Arthritis & Rheumatology, Clinical sciences
Abstract

ObjectiveIn cross-sectional studies, elevated osteopontin (OPN) levels have been proposed to reflect, and/or precede, progressive organ damage and disease severity in systemic lupus erythematosus (SLE). We aimed, in a cohort of patients with recent-onset SLE, to determine whether raised serum OPN levels precede damage and/or are associated with disease activity or certain disease phenotypes.MethodsWe included 344 patients from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort who had 5 years of followup data available. All patients fulfilled the 1997 American College of Rheumatology (ACR) criteria. Baseline sera from patients and from age- and sex-matched population-based controls were analyzed for OPN using ELISA. Disease activity and damage were assessed at each annual followup visit using the SLE Disease Activity Index 2000 (SLEDAI-2K) and the SLICC/ACR damage index (SDI), respectively.ResultsCompared to controls, baseline OPN was raised 4-fold in SLE cases (p < 0.0001). After relevant adjustments in a binary logistic regression model, OPN levels failed to significantly predict global damage accrual defined as SDI ≥ 1 at 5 years. However, baseline OPN correlated with SLEDAI-2K at enrollment into the cohort (r = 0.27, p < 0.0001), and patients with high disease activity (SLEDAI-2K ≥ 5) had raised serum OPN (p < 0.0001). In addition, higher OPN levels were found in patients with persistent disease activity (p = 0.0006), in cases with renal involvement (p < 0.0001) and impaired estimated glomerular filtration rate (p = 0.01).ConclusionThe performance of OPN to predict development of organ damage was not impressive. However, OPN associated significantly with lupus nephritis and with raised disease activity at enrollment, as well as over time.

Published
2019

16. O4 Clinical characteristics of patients with high SLE-specific and high multitrait polygenic risk – An investigation of SLE risk loci

Author

Oparina, Nina, primary, Reid, Sarah, additional, Sayadi, Ahmed, additional, Eloranta, Maija-Leena, additional, Frodlund, Martina, additional, Lerang, Karoline, additional, Jönsen, Andreas, additional, Rantapää-Dahlqvist, Solbritt, additional, Bengtsson, Anders A, additional, Rudin, Anna, additional, Molberg, Øyvind, additional, Sjöwall, Christopher, additional, Rönnblom, Lars, additional, and Leonard, Dag, additional

Published
2024
Full Text
View/download PDF

19. P145 Circulating interferon-α levels are elevated during pregnancy in women with SLE who deliver infants that are small for gestational age, preterm and/or have low birth weight

Author

Stockfelt, Marit, primary, Torell, Agnes, additional, Blennow, Kaj, additional, Zetterberg, Henrik, additional, Akhter, Tansim, additional, Leonard, Dag, additional, Rönnblom, Lars, additional, Pihl, Sofia, additional, Saleh, Muna, additional, Sjöwall, Christopher, additional, Strevens, Helena, additional, Jönsen, Andreas, additional, Bengtsson, Anders A, additional, Trysberg, Estelle, additional, Sennström, Maria Majcuk, additional, Zickert, Agneta, additional, Svenungsson, Elisabet, additional, Gunnarsson, Iva, additional, Jacobsson, Bo, additional, Lundell, Anna-Carin, additional, and Rudin, Anna, additional

Published
2024
Full Text
View/download PDF

20. P146 Low CD4+ T cell count is related to specific anti-nuclear antibodies, IFNα protein positivity and disease activity in systemic lupus erythematosus pregnancy

Author

Torell, Agnes, primary, Stockfelt, Marit, additional, Blennow, Kaj, additional, Zetterberg, Henrik, additional, Akhter, Tansim, additional, Leonard, Dag, additional, Rönnblom, Lars, additional, Pihl, Sofia, additional, Saleh, Muna, additional, Sjöwall, Christopher, additional, Strevens, Helena, additional, Jönsen, Andreas, additional, Bengtsson, Anders A, additional, Trysberg, Estelle, additional, Sennström, Maria Majcuk, additional, Zickert, Agneta, additional, Svenungsson, Elisabet, additional, Gunnarsson, Iva, additional, Bylund, Johan, additional, Jacobsson, Bo, additional, Rudin, Anna, additional, and Lundell, Anna-Carin, additional

Published
2024
Full Text
View/download PDF

22. P77 Identification of a cluster of SLE risk loci associated with levels of multiple blood biomarkers in the general population – Implication for SLE sub-phenotypes

Author

Oparina, Nina, primary, Reid, Sarah, additional, Sayadi, Ahmed, additional, Eloranta, Maija-Leena, additional, Frodlund, Martina, additional, Lerang, Karoline, additional, Jönsen, Andreas, additional, Rantapää-Dahlqvist, Solbritt, additional, Bengtsson, Anders A, additional, Rudin, Anna, additional, Molberg, Øyvind, additional, Sjöwall, Christopher, additional, Rönnblom, Lars, additional, and Leonard, Dag, additional

Published
2024
Full Text
View/download PDF

23. Variants in BANK1 are associated with lupus nephritis of European ancestry

Author

Bolin, Karin, Imgenberg-Kreuz, Juliana, Leonard, Dag, Sandling, Johanna K., Alexsson, Andrei, Pucholt, Pascal, Haarhaus, Malena Loberg, Almlöf, Jonas Carlsson, Nititham, Joanne, Jönsen, Andreas, Sjöwall, Christopher, Bengtsson, Anders A., Rantapää-Dahlqvist, Solbritt, Svenungsson, Elisabet, Gunnarsson, Iva, Syvänen, Ann-Christine, Lerang, Karoline, Troldborg, Anne, Voss, Anne, Molberg, Øyvind, Jacobsen, Søren, Criswell, Lindsey, Rönnblom, Lars, and Nordmark, Gunnel

Published
2021
Full Text
View/download PDF

24. Clinical Features and Long-Term Outcomes of Systemic Lupus Erythematosus.

Author

Sjöwall, Christopher, Parodis, Ioannis, and Sjöwall, Christopher

Subjects
Medicine, Afro-Caribbean, COVID-19, Ki/SL, MIR1279, SLE, SLEDAI-2K, Sjögren syndrome, Systemic Lupus Erythematosus, TNFSF4, abnormal liver function tests, autoantibodies, autoimmune hepatitis, autoimmune liver diseases, cancer, cardiovascular disease, chronic damage, classification, clinical follow-up, cluster analysis, comorbidities, compliance, cross-sectional studies, damage, dehydroepiandrosterone, disease activity, end-stage renal disease, epidemiology, fatigue, flare, genetics, glucocorticoids, health-related quality of life, hepatic involvement, hospital admissions, hydroxychloroquine, infections, laboratory, linear discriminant analysis, liver biopsy, long disease duration, long-term prognosis, low disease activity, low-disease activity, lupus, lupus nephritis, medication adherence, mood disorders, mortality, n/a, neoplasm, outcome, outcome measures, pain, patient outcome, patient perspective, patient-reported outcomes, polymorphisms, primary biliary cholangitis, proteasome, psychosocial, qualitative research, quality of life, remission, rheumatoid arthritis, surveys and questionnaires, survival, systemic lupus, systemic lupus erythematosus, trajectories
Abstract

Summary: The clinical spectrum of systemic lupus erythematosus (SLE) is highly heterogeneous, ranging from mild disease, which can be limited to skin and joint involvement, to life-threatening conditions with renal impairment, severe cytopenias, central nervous system disease, and thromboembolic events. Apart from the host genetics, several environmental factors, such as sunlight, infections, drugs, and probably hormonal factors, can trigger the onset of symptoms related to SLE. Despite significant advances in our understanding of the pathophysiology and optimization of medical care, patients with SLE still have significant rates of premature mortality and many patients experience severe disease with increased risk of sustaining organ damage and having a reduced health-related quality of life. The development of effective drugs that can induce remission or low disease activity, the unanimous use of definitions of remission and low or high disease activity, flare, and response to therapy, the identification of non-invasive biomarkers of disease activity and long-term outcomes, and the implementation of SLE patients' perspectives as an integral part of the clinical assessment constitute only a few of the many unmet needs in the field of SLE.

25. Transancestral mapping and genetic load in systemic lupus erythematosus.

Author

Langefeld, Carl D, Ainsworth, Hannah C, Cunninghame Graham, Deborah S, Kelly, Jennifer A, Comeau, Mary E, Marion, Miranda C, Howard, Timothy D, Ramos, Paula S, Croker, Jennifer A, Morris, David L, Sandling, Johanna K, Almlöf, Jonas Carlsson, Acevedo-Vásquez, Eduardo M, Alarcón, Graciela S, Babini, Alejandra M, Baca, Vicente, Bengtsson, Anders A, Berbotto, Guillermo A, Bijl, Marc, Brown, Elizabeth E, Brunner, Hermine I, Cardiel, Mario H, Catoggio, Luis, Cervera, Ricard, Cucho-Venegas, Jorge M, Dahlqvist, Solbritt Rantapää, D'Alfonso, Sandra, Da Silva, Berta Martins, de la Rúa Figueroa, Iñigo, Doria, Andrea, Edberg, Jeffrey C, Endreffy, Emőke, Esquivel-Valerio, Jorge A, Fortin, Paul R, Freedman, Barry I, Frostegård, Johan, García, Mercedes A, de la Torre, Ignacio García, Gilkeson, Gary S, Gladman, Dafna D, Gunnarsson, Iva, Guthridge, Joel M, Huggins, Jennifer L, James, Judith A, Kallenberg, Cees GM, Kamen, Diane L, Karp, David R, Kaufman, Kenneth M, Kottyan, Leah C, Kovács, László, Laustrup, Helle, Lauwerys, Bernard R, Li, Quan-Zhen, Maradiaga-Ceceña, Marco A, Martín, Javier, McCune, Joseph M, McWilliams, David R, Merrill, Joan T, Miranda, Pedro, Moctezuma, José F, Nath, Swapan K, Niewold, Timothy B, Orozco, Lorena, Ortego-Centeno, Norberto, Petri, Michelle, Pineau, Christian A, Pons-Estel, Bernardo A, Pope, Janet, Raj, Prithvi, Ramsey-Goldman, Rosalind, Reveille, John D, Russell, Laurie P, Sabio, José M, Aguilar-Salinas, Carlos A, Scherbarth, Hugo R, Scorza, Raffaella, Seldin, Michael F, Sjöwall, Christopher, Svenungsson, Elisabet, Thompson, Susan D, Toloza, Sergio MA, Truedsson, Lennart, Tusié-Luna, Teresa, Vasconcelos, Carlos, Vilá, Luis M, Wallace, Daniel J, Weisman, Michael H, Wither, Joan E, Bhangale, Tushar, Oksenberg, Jorge R, Rioux, John D, Gregersen, Peter K, Syvänen, Ann-Christine, Rönnblom, Lars, Criswell, Lindsey A, Jacob, Chaim O, Sivils, Kathy L, Tsao, Betty P, Schanberg, Laura E, and Behrens, Timothy W

Subjects
Humans, Lupus Erythematosus, Systemic, HLA Antigens, Logistic Models, Case-Control Studies, Mutagenesis, Insertional, Age of Onset, Sequence Deletion, Genetic Load, Multifactorial Inheritance, Polymorphism, Single Nucleotide, African Continental Ancestry Group, American Native Continental Ancestry Group, European Continental Ancestry Group, Hispanic Americans, Lupus Erythematosus, Systemic, Mutagenesis, Insertional, Polymorphism, Single Nucleotide
Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease with marked gender and ethnic disparities. We report a large transancestral association study of SLE using Immunochip genotype data from 27,574 individuals of European (EA), African (AA) and Hispanic Amerindian (HA) ancestry. We identify 58 distinct non-HLA regions in EA, 9 in AA and 16 in HA (∼50% of these regions have multiple independent associations); these include 24 novel SLE regions (P

Published
2017

27. Correction: Antigen-presenting autoreactive B cells activate regulatory T cells and suppress autoimmune arthritis in mice

Author

Aoun, Mike, primary, Coelho, Ana, additional, Krämer, Alexander, additional, Saxena, Amit, additional, Sabatier, Pierre, additional, Beusch, Christian Michel, additional, Lönnblom, Erik, additional, Geng, Manman, additional, Do, Nhu-Nguyen, additional, Xu, Zhongwei, additional, Zhang, Jingdian, additional, He, Yibo, additional, Castillo, Laura Romero, additional, Abolhassani, Hassan, additional, Xu, Bingze, additional, Viljanen, Johan, additional, Rorbach, Joanna, additional, Lahore, Gonzalo Fernandez, additional, Gjertsson, Inger, additional, Kastbom, Alf, additional, Sjöwall, Christopher, additional, Kihlberg, Jan, additional, Zubarev, Roman A., additional, Burkhardt, Harald, additional, and Holmdahl, Rikard, additional

Published
2023
Full Text
View/download PDF

28. B cell polygenic risk scores associate with anti-dsDNA antibodies and nephritis in systemic lupus erythematosus

Author

Hedenstedt, Anna, primary, Reid, Sarah, additional, Sayadi, Ahmed, additional, Eloranta, Maija-Leena, additional, Skoglund, Elisabeth, additional, Bolin, Karin, additional, Frodlund, Martina, additional, Lerang, Karoline, additional, Jönsen, Andreas, additional, Rantapää-Dahlqvist, Solbritt, additional, Bengtsson, Anders A, additional, Rudin, Anna, additional, Molberg, Øyvind, additional, Sjöwall, Christopher, additional, Sandling, Johanna K, additional, and Leonard, Dag, additional

Published
2023
Full Text
View/download PDF

31. Belimumab and antimalarials combined against renal flares in patients treated for extra-renal systemic lupus erythematosus: results from 4 phase III clinical trials.

Author

Gomez, Alvaro, Jägerback, Sandra, Sjöwall, Christopher, and Parodis, Ioannis

Subjects
DRUG efficacy, STATISTICS, BIOMARKERS, COMBINATION drug therapy, LUPUS nephritis, INTRAVENOUS therapy, CONFIDENCE intervals, B cells, URINE, SUPPURATION, REGRESSION analysis, DISEASE relapse, SEVERITY of illness index, COMPARATIVE studies, RESEARCH funding, DESCRIPTIVE statistics, PROTEINURIA, QUESTIONNAIRES, ANTIMALARIALS, DATA analysis, HEMATURIA, DATA analysis software, PREDNISONE, IMMUNOSUPPRESSIVE agents, STATISTICAL models, BELIMUMAB, SUBCUTANEOUS injections, LONGITUDINAL method, PROPORTIONAL hazards models, CREATININE
Abstract

Objectives To determine the effect of antimalarial agents (AMA) and different doses and pharmaceutical forms of belimumab on preventing renal flares in patients with SLE treated for extra-renal disease. Methods We pooled data from the BLISS-52, BLISS-76, BLISS-SC and BLISS-Northeast Asia trials of belimumab (n  = 3225), that included patients with active SLE yet no severe ongoing nephritis. Participants were allocated to receive intravenous belimumab 1 mg/kg, intravenous belimumab 10 mg/kg, subcutaneous belimumab 200 mg, or placebo in addition to standard therapy. We estimated hazards of renal flare development throughout the study follow-up (52–76 weeks) using Cox regression analysis. Results In total, 192 patients developed a renal flare after a median of 197 days. Compared with placebo, the risk of renal flares was lower among patients receiving intravenous belimumab 10 mg/kg (HR: 0.62; 95% CI: 0.41, 0.92; P  = 0.018) and intravenous belimumab 1 mg/kg (HR: 0.42; 95% CI: 0.22, 0.79; P  = 0.007), while no significant association was found for subcutaneous belimumab 200 mg. AMA use yielded a lower hazard of renal flares (HR: 0.66; 95% CI: 0.55, 0.78; P  < 0.001). The protection conferred was enhanced when belimumab and AMA were co-administered; the lowest flare rate was observed for the combination intravenous belimumab 1 mg/kg and AMA (18.5 cases per 1000 person-years). Conclusions The protection conferred from belimumab against renal flare development in patients treated for extra-renal SLE appears enhanced when belimumab was administered along with AMA. The prominent effect of low-dose belimumab warrants investigation of the efficacy of intermediate belimumab doses. Clinical trial identification BLISS-52: NCT00424476; BLISS-76: NCT00410384; BLISS-SC: NCT01484496; BLISS-NEA: NCT01345253. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Antigen-presenting autoreactive B cells activate regulatory T cells and suppress autoimmune arthritis in mice

Author

Aoun, Mike, primary, Coelho, Ana, additional, Krämer, Alexander, additional, Saxena, Amit, additional, Sabatier, Pierre, additional, Beusch, Christian Michel, additional, Lönnblom, Erik, additional, Geng, Manman, additional, Do, Nhu-Nguyen, additional, Xu, Zhongwei, additional, Zhang, Jingdian, additional, He, Yibo, additional, Romero Castillo, Laura, additional, Abolhassani, Hassan, additional, Xu, Bingze, additional, Viljanen, Johan, additional, Rorbach, Joanna, additional, Fernandez Lahore, Gonzalo, additional, Gjertsson, Inger, additional, Kastbom, Alf, additional, Sjöwall, Christopher, additional, Kihlberg, Jan, additional, Zubarev, Roman A., additional, Burkhardt, Harald, additional, and Holmdahl, Rikard, additional

Published
2023
Full Text
View/download PDF

33. Extracellular vesicles opsonized by monomeric C-reactive protein (CRP) are accessible as autoantigens in patients with systemic lupus erythematosus and associate with autoantibodies against CRP

Author

Karlsson, Jesper, primary, Wetterö, Jonas, additional, Potempa, Lawrence A., additional, Fernandez-Botran, Rafael, additional, O'Neill, Yasmine, additional, Wirestam, Lina, additional, Mobarrez, Fariborz, additional, and Sjöwall, Christopher, additional

Published
2023
Full Text
View/download PDF

34. Pentameric C-reactive protein is a better prognostic biomarker and remains elevated for longer than monomeric CRP in hospitalized patients with COVID-19

Author

Hopkins, Francis R., primary, Nordgren, Johan, additional, Fernandez-Botran, Rafael, additional, Enocsson, Helena, additional, Govender, Melissa, additional, Svanberg, Cecilia, additional, Svensson, Lennart, additional, Hagbom, Marie, additional, Nilsdotter-Augustinsson, Åsa, additional, Nyström, Sofia, additional, Sjöwall, Christopher, additional, Sjöwall, Johanna, additional, and Larsson, Marie, additional

Published
2023
Full Text
View/download PDF

38. A rare regulatory variant in the MEF2D gene affects gene regulation and splicing and is associated with a SLE sub-phenotype in Swedish cohorts

Author

Farias, Fabiana H. G., Dahlqvist, Johanna, Kozyrev, Sergey V., Leonard, Dag, Wilbe, Maria, Abramov, Sergei N., Alexsson, Andrei, Pielberg, Gerli R., Hansson-Hamlin, Helene, Andersson, Göran, Tandre, Karolina, Bengtsson, Anders A., Sjöwall, Christopher, Svenungsson, Elisabet, Gunnarsson, Iva, Rantapää-Dahlqvist, Solbritt, Syvänen, Ann-Christine, Sandling, Johanna K., Eloranta, Maija-Leena, Rönnblom, Lars, and Lindblad-Toh, Kerstin

Published
2019
Full Text
View/download PDF

45. Autoantibodies to Disease‐Related Proteins in Joints as Novel Biomarkers for the Diagnosis of Rheumatoid Arthritis

Author

Lönnblom, Erik, primary, Leu Agelii, Monica, additional, Sareila, Outi, additional, Cheng, Lei, additional, Xu, Bingze, additional, Viljanen, Johan, additional, Hafström, Ingiäld, additional, Andersson, Maria L. E., additional, Bergström, Göran, additional, Hultgård Ekwall, Anna‐Karin, additional, Rudin, Anna, additional, Kastbom, Alf, additional, Sjöwall, Christopher, additional, Jacobsson, Lennart T. H., additional, Kihlberg, Jan, additional, Gjertsson, Inger, additional, and Holmdahl, Rikard, additional

Published
2023
Full Text
View/download PDF

47. Additional file 2 of Low-density granulocytes are related to shorter pregnancy duration but not to interferon alpha protein blood levels in systemic lupus erythematosus

Author

Torell, Agnes, Stockfelt, Marit, Larsson, Gunilla, Blennow, Kaj, Zetterberg, Henrik, Leonard, Dag, Rönnblom, Lars, Saleh, Muna, Sjöwall, Christopher, Strevens, Helena, Jönsen, Andreas, Bengtsson, Anders A., Trysberg, Estelle, Sennström, Maria Majcuk, Zickert, Agneta, Svenungsson, Elisabet, Gunnarsson, Iva, Christenson, Karin, Bylund, Johan, Jacobsson, Bo, Rudin, Anna, and Lundell, Anna-Carin

Abstract

Additional file 2: Supplementary Table 1. Numbers of collected blood samples. Supplementary Table 2. Antibodies used for flow cytometry.

Published
2023
Full Text
View/download PDF

48. Additional file 1 of Low-density granulocytes are related to shorter pregnancy duration but not to interferon alpha protein blood levels in systemic lupus erythematosus

Author

Torell, Agnes, Stockfelt, Marit, Larsson, Gunilla, Blennow, Kaj, Zetterberg, Henrik, Leonard, Dag, Rönnblom, Lars, Saleh, Muna, Sjöwall, Christopher, Strevens, Helena, Jönsen, Andreas, Bengtsson, Anders A., Trysberg, Estelle, Sennström, Maria Majcuk, Zickert, Agneta, Svenungsson, Elisabet, Gunnarsson, Iva, Christenson, Karin, Bylund, Johan, Jacobsson, Bo, Rudin, Anna, and Lundell, Anna-Carin

Abstract

Additional file 1: Supplementary figure 1. (A) Expression of CD15 and CD14 on low-density granulocytes (LDG) from two pregnant women with SLE (two left panels, samples from trimester three) and two healthy pregnant controls (HC, two right panels, one sample from trimester three and one sample from trimester one). (B) Analysis of proportions of LDG and shedding of CD62L by NDG in blood from pregnant women with SLE and healthy pregnant controls between 17 and 24 h post venipuncture i.e., the time span when all samples in the study were analyzed. (C) Analysis of total number of granulocytes, proportions of LDG and shedding of CD62L by normal-density granulocytes (NDG) from one pregnant woman with SLE in trimester three and one healthy pregnant control in trimester one at 5 and 24 h post venipuncture. Supplementary figure 2. Comparison of (A) proportions of low-density granulocytes (LDG), (B) proportions of LDG that have shed CD62L, (C) proportions of normal-density granulocytes (NDG) that have shed CD62L and (D) total granulocyte counts during compared to after pregnancy among women with SLE from whom late postpartum samples were collected. *p < 0.05, **p < 0.01 and ***p < 0.001, Kruskal-Wallis followed by Dunn’s multiple comparison test. Supplementary figure 3. Comparison of LDG proportions in pregnant women with SLE with or without a moderate/high disease activity (SLEDAI-2K ≥ 4) in (A) trimester one, (B) trimester two and (C) trimester three. Mann-Whitney U test. Supplementary figure 4. Comparison of (A) LDG proportions, (B) LDG activation by CD62L shedding, (C) NDG activation by CD62L shedding and (D) IFNα protein levels in SLE and healthy pregnancy for each trimester. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 Mann-Whitney U test. Supplementary figure 5. Comparison of the proportions of low-density granulocytes (LDG) and normal-density granulocytes (NDG) that have shed CD62L in pregnant women with SLE and in healthy pregnant controls (HC). **** p < 0.0001, Mann-Whitney U test. Supplementary figure 6. Concentrations of G-CSF (A) and GM-CSF (B) in plasma during pregnancy (first, second and third trimester) compared to the late postpartum period among women with SLE from whom late postpartum samples were collected. Concentrations of G-CSF (C) and GM-CSF (D) in plasma in the first, second and third trimester in SLE compared to healthy pregnancies. Supplementary figure 7. (A) OPLS loading column plot depicting granulocyte-related immune variables positively or negatively associated with prednisone use in SLE pregnancy, and low-density proportions in pregnant women with SLE who were treated with prednisone compared to those who were not treated. (B) OPLS plot depicting granulocyte-related immune variables positively or negatively associated with azathioprine use in SLE pregnancy and CD62L shedding of normal-density granulocytes in pregnant women with SLE who were treated with azathioprine compared to those who were not treated. (C) OPLS plot depicting granulocyte-related immune variables positively or negatively associated with low molecular weight heparin use in SLE pregnancy. * p < 0.05, Mann-Whitney U test. Supplementary figure 8. IFNα plasma protein concentrations in trimester one, two and three from pregnant women with SLE who were treated or not with prednisone (A), azathioprine (B) or low molecular weight heparin (C). Supplementary figure 9. IFNα plasma protein concentrations in trimester one, two and three from pregnant women with SLE who were anti-SSA positive compared to those who were negative. ** p < 0.01, Mann-Whitney U test. Supplementary figure 10. (A) Gestational age at birth among women with SLE with induced compared to spontaneous delivery. (B) Gestational age at birth in women with SLE with induced or spontaneous delivery who were positive or negative for anti-CL, anti-β2GPI or LAC. (C) Correlations between gestational age at birth and proportions of LDG in trimester three, two and one among women with SLE with induced or spontaneous delivery. * p < 0.05, (B) Mann-Whitney U test and (C) Spearman rank correlation test.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results